• Arcutis Biotherapeutics granted 143,500 restricted stock units, with 37,000 stock options, to 24 newly hired employees under its 2022 Inducement Plan.
• RSUs vest over four years, with 25% vesting on each annual anniversary, subject to continued employment.
• Options vest over four years; 25% vests after one year, with the remainder vesting in equal monthly installments over three years.
• Options carry a 10-year term, with an exercise price of $25.94 per share, set on Aug. 3, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcutis Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608071600PRIMZONEFULLFEED9805784) on August 07, 2026, and is solely responsible for the information contained therein.